TAGLN3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P10292(TAGLN3 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P10292(TAGLN3 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

The TAGLN3 antibody targets Transgelin-3 (TAGLN3), a member of the calponin-transgelin family of actin-binding proteins involved in cytoskeletal remodeling. TAGLN3 is encoded by the TAGLN3 gene and shares structural homology with other transgelin isoforms, including a conserved calponin-like domain that mediates interactions with actin filaments. Primarily expressed in the central nervous system (CNS) and immune cells, TAGLN3 is implicated in neuronal development, synaptic plasticity, and T-cell activation. Studies suggest its role in regulating cell motility, differentiation, and immune synapse formation. Dysregulation of TAGLN3 has been linked to neurological disorders (e.g., Alzheimer’s disease), autoimmune conditions, and cancers, where it may influence tumor invasiveness or immune evasion.

TAGLN3 antibodies are widely used in research to detect protein expression via techniques like Western blotting, immunohistochemistry, and flow cytometry. These tools help elucidate TAGLN3’s localization, interaction partners, and mechanistic roles in health and disease. However, antibody specificity remains a challenge due to sequence similarities among transgelin isoforms. Validation using knockout controls or siRNA is recommended. Commercial TAGLN3 antibodies vary in clonality (monoclonal/polyclonal) and host species, with common applications in neuroscience, immunology, and oncology research. Ongoing studies aim to clarify its dual roles in neuroprotection and pathology, as well as its potential as a therapeutic target.